Surgery Partners (SGRY) and Bain Capital Conclude Discussions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Surgery Partners (SGRY) guidance reaffirmation 'positive' despite no Bain deal - Mizuho
June 17, 2025 3:22 PM EDTMizuho analyst Ann Hynes reiterated an Outperform rating and a $28.00 price target on Surgery Partners (NASDAQ: SGRY) amid today's sell-off, following the company's announcement that it has concluded its discussions with Bain Capital regarding a potential acquisition. The company's independent committee determined that its long-term potential as an independent, publicly-traded company... More
